You are here

Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media

Last updated on May 12, 2018

FOR MORE INFORMATION
Study Location
Auch, , 32000 France
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Otitis Media, Otitis Media With Effusion, Pneumococcal Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-24 months
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Infants aged from 6 to 24 months

- Presenting with AOM (ear infection)

- Patients must not have received any antibiotic therapy within the past 7 days.

Other inclusion applies.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
NCT00195611
Pfizer
Completed
Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Respiratory Tract Infections
NCT03529773
All Genders
18+
Years
Multiple Sites
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
NCT03330405
All Genders
18+
Years
Multiple Sites
Pneumococcal Infections
NCT03512288
All Genders
0+
Years
Multiple Sites
Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media
Observational Study of the Rhinopharyngeal Carriage of Streptococcus Pneumoniae (Sp) in Infants With Acute Otitis Media (AOM)
The aim of this study is to assess in France the impact of Prevenar on the possible evolution of the pneumococcal serotypes distribution and antibiotic resistance in NP samples of children with AOM.
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Screening, Cross-Sectional, Defined Population, Prospective Study
  • Otitis Media
  • Otitis Media With Effusion
  • Pneumococcal Infections
Drug: Prevenar
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3293
June 2006
June 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Infants aged from 6 to 24 months
  • Presenting with AOM (ear infection)
  • Patients must not have received any antibiotic therapy within the past 7 days.

Other inclusion applies.

Exclusion Criteria:

Sexes Eligible for Study: All
6 Months to 24 Months   (Child)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00195611
0887X-100918
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
June 2010

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now